Article Text

Download PDFPDF
Trends in Treatment and Survival of Late-Stage Squamous Cell Vulvar Carcinomas: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
  1. Rajeev Ramanah, MD*,,
  2. Bénédicte Lesieur, MD*,
  3. Marcos Ballester, MD*,
  4. Emile Darai, MD, PhD*, and
  5. Roman Rouzier, MD, PhD*,
  1. *Obstetrics and Gynecology Department, Tenon Hospital, 4 Rue de la Chine, Paris, France,
  2. Obstetrics and Gynecology Department, Besancon University Medical Center, Besancon, France; and
  3. University Pierre et Marie Curie of Paris, France.
  1. Address correspondence and reprint requests to Roman Rouzier, MD, PhD, Obstetrics and Gynecology Department, Tenon Hospital, 4 Rue de la Chine, 75020 Paris, France. E-mail: roman.rouzier@tnn.aphp.fr.

Abstract

Objective To describe the trends in the rate, treatment, and survival of late-stage vulvar carcinomas (LSVCs) over a 20-year period in the United States.

Methods Demographic, pathologic, treatment, and survival data were collected from the Surveillance, Epidemiology, and End Results registry between 1988 and 2007. Trends concerning the rate of LSVC (International Federation of Gynecology and Obstetrics [FIGO] stages III and IV), its management, and outcome were studied. Five-year overall and disease-specific survival rates were calculated.

Results The rate of LSVC (32.4%) as compared with early-stage disease (67.6%) did not change significantly from 1988 to 2007 (P = 0.59). Of the 2630 patients with LSVC, the median age at diagnosis was 72 years, with 88.5% of them being white. Surgery and radiation therapy were performed in 73.8% and 60.6% of cases, respectively, with 37% of the patients having no lymph node dissection. A significant trend toward removing fewer lymph nodes (P = 0.02) and offering more radiation therapy (P = 0.02) has been observed across the study period. Five-year overall and disease-specific survival rates did not change (P = 0.44 and P =0.26, respectively) from 1988 to 2007. On multivariate analysis, node positivity (hazard ratio, 3.12 [95% confidence interval, 2.30–4.24]) and surgery (hazard ratio, 0.41 [95% confidence interval, 0.24–0.69]) were found to be the 2 most predictive variables for cancer mortality, followed by age and tumor size.

Conclusion Less extensive surgery and more radiation therapy did not compromise survival of LSVC over the 20-year period.

  • Late-stage disease
  • Squamous cell vulvar carcinoma
  • Survival
  • Treatment

Statistics from Altmetric.com

Footnotes

  • The authors have no conflicts of interest to declare.

  • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.ijgc.net).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.